Molecular genetics of osteosarcoma

K Rickel, F Fang, J Tao - Bone, 2017 - Elsevier
Osteosarcoma is the predominant form of bone cancer, affecting mostly adolescents. Recent
progress made in molecular genetic studies of osteosarcoma has changed our view on the …

Mechanisms of resistance to conventional therapies for osteosarcoma

L Marchandet, M Lallier, C Charrier, M Baud'huin… - Cancers, 2021 - mdpi.com
Simple Summary Osteosarcoma (OS), the most common primary bone tumor, mainly affects
children and adolescents. Unfortunately, in some cases, the absence of response to …

Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers

GA Odri, J Tchicaya-Bouanga, DJY Yoon, D Modrowski - Cancers, 2022 - mdpi.com
Simple Summary Osteosarcomas are heterogeneous bone tumors with complex genetic and
chromosomic alterations. The numerous patients with metastatic osteosarcoma have a very …

Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies

R Rathore, BA Van Tine - Journal of clinical medicine, 2021 - mdpi.com
Osteosarcoma is the most common primary malignant bone tumor in children and young
adults. The standard-of-care curative treatment for osteosarcoma utilizes doxorubicin …

Deciphering the signaling mechanisms of osteosarcoma tumorigenesis

BK Nirala, T Yamamichi, JT Yustein - International Journal of Molecular …, 2023 - mdpi.com
Osteosarcoma (OS) is the predominant primary bone tumor in the pediatric and adolescent
populations. It has high metastatic potential, with the lungs being the most common site of …

Lnc RNA SNHG 4 promotes tumour growth by sponging miR‐224‐3p and predicts poor survival and recurrence in human osteosarcoma

R Xu, F Feng, X Yu, Z Liu, L Lao - Cell proliferation, 2018 - Wiley Online Library
Objective Accumulating data show that dysregulation of long noncoding RNA s (lnc RNA s)
acts a critical role in a variety of malignancies. Among these lnc RNA s, small nucleolar RNA …

[HTML][HTML] lncRNA SNHG10 promotes the proliferation and invasion of osteosarcoma via wnt/β-catenin signaling

S Zhu, Y Liu, X Wang, J Wang, G Xi - Molecular Therapy-Nucleic Acids, 2020 - cell.com
Uncontrolled growth and an enforced epithelial-mesenchymal transition (EMT) process
contribute to the poor survival rate of patients with osteosarcoma (OS). Long noncoding …

SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT …

SJ Zhao, YQ Jiang, NW Xu, Q Li, Q Zhang, SY Wang… - Oncogene, 2018 - nature.com
Metastasis significantly reduces the survival rate of osteosarcoma (OS) patients. Therefore,
identification of novel targets remains extremely important to prevent metastasis and treat …

Advances in differentiation therapy for osteosarcoma

Y Chen, J Cao, N Zhang, B Yang, Q He, X Shao… - Drug discovery today, 2020 - Elsevier
Highlights•Osteosarcoma is a disease resulting from osteogenic differentiation
defects.•Differentiation therapy for osteosarcoma has received extensive attention.•Various …

miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma

RD Xu, F Feng, XS Yu, ZD Liu… - International journal of …, 2018 - journals.sagepub.com
MicroRNAs (miRNAs) as small non-coding RNAs act as either tumor suppressors or
oncogenes in human cancers, of which miR-149-5p (miR-149) is involved in tumor growth …